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InsBACKGROUND Brain lesions on diffusion-weighted imaging (DWI) are frequently found after carotid artery stenting
(CAS), but their clinical relevance remains unclear.
OBJECTIVES This study sought to investigate whether periprocedural ischemic DWI lesions after CAS or carotid end-
arterectomy (CEA) are associated with an increased risk of recurrent cerebrovascular events.
METHODS In the magnetic resonance imaging (MRI) substudy of ICSS (International Carotid Stenting Study), 231
patients with symptomatic carotid stenosis were randomized to undergo CAS (n ¼ 124) or CEA (n ¼ 107). MRIs were
performed 1 to 7 days before and 1 to 3 days after treatment. The primary outcome event was stroke or transient ischemic
attack in any territory occurring between the post-treatment MRI and the end of follow-up. Time to occurrence of the
primary outcome event was compared between patients with (DWIþ) and without (DWI–) new DWI lesions on the post-
treatment scan in the CAS and CEA groups separately.
RESULTS Median time of follow-up was 4.1 years (interquartile range: 3.0 to 5.2). In the CAS group, recurrent stroke or
transient ischemic attack occurred more often among DWIþ patients (12 of 62) than among DWI– patients (6 of 62), with
a cumulative 5-year incidence of 22.8% (standard error [SE]: 7.1%) and 8.8% (SE: 3.8%), respectively (unadjusted hazard
ratio: 2.85; 95% confidence interval: 1.05 to 7.72; p ¼ 0.04). In DWIþ and DWI– patients, 8 and 2 events, respectively,
occurred within 6 months after treatment. In the CEA group, there was no difference in recurrent cerebrovascular events
between DWIþ and DWI– patients.
CONCLUSIONS Ischemic brain lesions discovered on DWI after CAS seem to be a marker of increased risk for recurrent
cerebrovascular events. Patients with periprocedural DWI lesions might benefit from more aggressive and prolonged
antiplatelet therapy after CAS. (A Randomised Comparison of the Risks, Benefits and Cost Effectiveness of Primary
Carotid Stenting With Carotid Endarterectomy: International Carotid Stenting Study; ISRCTN25337470) (J Am Coll
Cardiol 2015;65:521–9) © 2015 by the American College of Cardiology Foundation.m the *Department of Neurology and Stroke Center, University Hospital Basel, Basel, Switzerland; yDepartment of Neurology
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ARWMC = age-related white
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CEA = carotid endarterectomy
DWI = diffusion-weighted
imaging
FLAIR = fluid-attenuated
inversion recovery
MRI = magnetic
resonance imaging
TIA = transient ischemic attack
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522T he occurrence of periproceduralischemic brain lesions on magneticresonance imaging (MRI) after re-
vascularization of atherosclerotic stenosis
of the internal carotid artery, either with
stenting (CAS) or endarterectomy (CEA), has
been commonly described (1). The random-
ized ICSS (International Carotid Stenting
Study) compared CAS with CEA in patients
with symptomatic carotid stenosis (2). In
the MRI substudy of ICSS (ICSS-MRI), 50%
of patients treated with CAS and 17% of those
undergoing CEA had periprocedural ischemic
brain lesions on diffusion-weighted imaging(DWI) on MRI scans obtained a median of 1 day after
treatment (adjusted odds ratio 5.21; 95% confidence
interval [CI]: 2.78 to 9.79; p < 0.0001) (3). However,
the clinical significance of these lesions remains un-
clear. Previous research focused mainly on the persis-
tence of lesions on follow-up imaging (4–7) and their
effects on neuropsychological function (8–10).SEE PAGE 530The goal of the present analysis of the ICSS-MRI sub-
study was to investigate whether the occurrence of
periprocedural DWI lesions altered the risk of future
cerebrovascular events during long-term follow-up.
METHODS
The prospective multicenter ICSS-MRI substudy
included 124 patients randomly assigned to CAS and
107 patients randomly assigned to CEA in ICSS. The
study design and themain short- and long-term results
of ICSS and the ICSS-MRI substudy have been reportedcht, Utrecht, the Netherlands. ICSS (International Carotid Stent
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symptomatic moderate or severe carotid stenosis
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the measurement of degree of stenosis used in the
North American Symptomatic Carotid Endarterectomy
Trial [12]) were randomized in a 1:1 ratio to receive CAS
or CEA. Baseline imaging of the target artery was
specified to require consistent findings on at least 2
noninvasive imaging modalities, including computed
tomography angiography, magnetic resonance angi-
ography, and duplex ultrasound; or intra-arterial
digital subtraction angiography. Eight patients in the
CAS group and 7 patients in the CEA group underwent
digital subtraction angiography before the randomly
allocated procedure, and the remainder received
noninvasive imaging. The protocol recommended the
use of a cerebral protection device during CAS when-
ever such a device could be safely deployed, but this
action was not mandatory. The combination of aspirin
and clopidogrel was recommended to cover the period
of stenting and to be continued for a minimum of 4
weeks after the procedure.
If no contraindications to MRI were present, all
patients included at 7 ICSS centers had the option of
participating in the ICSS-MRI substudy (Figure 1). MRI
scans at field strengths of 1.5- or 3-T (including DWI
and fluid-attenuated inversion recovery [FLAIR]
sequences) were specified to be conducted 1 to 7 days
before treatment (pre-treatment MRI) and 1 to 3 days
after treatment (post-treatment MRI). Assessment of
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FIGURE 1 Study Flow Diagram
379 patients randomized
189 allocated CAS
149 underwent
pre-treatment scan
131 underwent
pre-treatment scan
147 CAS initiated 129 CEA initiated
129 CEA completed142 CAS completed
126 underwent
post-treatment scan
107 underwent
post-treatment scan
124 included in analysis 107 included in analysis
1 received BMT only
2 DWI not done
2 DWI quality insufficient
1 fatal periprocedural MI
1 fatal periprocedural stroke
1 no post-treatment scan for medical reasons
1 withdrew consent for post-treatment scan
12 MRI scanner unavailable after treatment
1 fatal periprocedural stroke
7 no post-treatment scan for medical reasons
1 withdrew consent for post-treatment scan
13 MRI scanner unavailable after treatment
5 CAS aborted (3 received CEA,
2 received BMT only)
10 MRI contraindicated
2 no consent to MRI substudy
27 MRI scanner unavailable before treatment
190 allocated CEA
2 received CAS
5 received BMT only
9 MRI contraindicated
1 no pre-treatment scan for medical reasons
3 no consent to MRI Study
39 MRI scanner unavailable before treatment
1 probable sudden cardiac death before
treatment
1 patient withdrew consent for treatment and 
received BMT only
Diagram outlining the 2 arms of the study, including events that precluded patients from analysis. Scans are magnetic resonance imaging (MRI). BMT ¼ best medical
treatment; CAS ¼ carotid artery stenting; CEA ¼ carotid endarterectomy; DWI ¼ diffusion-weighted imaging; MI ¼ myocardial infarction.
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523the 2 reviewers, a third reviewer (S.T.E.) made the
final decision. New periprocedural ischemic brain
lesions were defined as hyperintense DWI lesions on
the post-treatment MRI that were not present on the
pre-treatment MRI. Furthermore, the number (lesion
count) and total and individual volumes of new DWI
lesions were assessed in each patient. Age-related
white matter changes (ARWMC) on the baseline scan
were quantified on pre-treatment FLAIR sequences
by using a published scale (13).
In ICSS, patients were followed up for 30 days after
treatment and then at 6 months and annually after
randomization by clinicians who were not involved in
delivering the treatment. Outcome events were
recorded at the centers, reported to the study office,and centrally adjudicated by the chief investigator.
An independent external adjudicator who was blin-
ded to treatment allocation also received the outcome
events, including death or stroke.
The primary combined outcome event of the pre-
sent analysis was stroke or transient ischemic attack
(TIA) located in any vascular territory, occurring
between the post-treatment MRI scan and the end of
available follow-up. Stroke was defined as a rapidly
developing clinical syndrome of focal disturbance of
cerebral function lasting >24 h or leading to death
with no apparent cause other than that of vascular
origin. TIA was defined as a rapidly developing clin-
ical syndrome of focal disturbance of cerebral func-
tion lasting <24 h with no apparent cause other than
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524cerebral ischemia. Secondary outcome events were
stroke or TIA occurring in the territory supplied by
the treated carotid artery and stroke alone occurring
in any territory.
Patients in the CAS group and the CEA group
were analyzed separately. The relation between new
periprocedural DWI lesions and time until occurrence
of cerebrovascular events during follow-up was
analyzed in 2 different ways: first, by the presence
(DWIþ) or absence (DWI–) of periprocedural DWI
lesions (binary analysis); and second, by the absolute
number of periprocedural DWI lesions (count ana-
lysis). The following baseline variables were assessed
for adjustment of the analyses: age, sex, history of
vascular risk factors (any smoking [current or past],
diabetes, hypertension, hyperlipidemia, coronary
heart disease, or peripheral artery disease), systolic
blood pressure, total serum cholesterol, modified
Rankin Scale (14), type of qualifying event (defined as
the most recent ipsilateral ischemic event before
randomization [retinal ischemia, TIA, or hemispheric
stroke]), the ARWMC sum score (13), degree of ipsi-
lateral and contralateral stenosis (mild 30% to 49%;
moderate 50% to 69%; and severe 70% to 99%), and
the presence or absence of hyperintense DWI lesions
on pre-treatment MRI.
STANDARD PROTOCOL APPROVALS, REGISTRATIONS,
AND PATIENT CONSENT. The North West Multi-
Centre Research Ethics Committee in the United
Kingdom and local ethics committees for non–United
Kingdom centers approved the study. All patients
provided written informed consent.
STATISTICAL ANALYSIS. Demographic and clinical
baseline characteristics were compared between pa-
tients with and without new DWI lesions after treat-
ment by using the Fisher exact test or the chi-square
test as appropriate for categorical variables and the
Mann-Whitney U test for continuous variables. In the
binary analysis, we compared the time until occur-
rence of an outcome event between DWIþ and DWI–
patients (with the latter as the reference group) by
using Cox proportional hazards regression models to
calculate hazard ratios (HRs) with 95% CIs. The pro-
portional hazards assumption was checked with test
results and diagnostic plots on the basis of scaled
Schoenfeld residuals. In the lesion count analysis, the
association between the number of new periproce-
dural DWI lesions and time until occurrence of an
outcome event were analyzed by using Cox regres-
sion models. In the case of occurrence of multiple
strokes or TIAs, only the first event qualifying as an
outcome event was counted. Kaplan-Meier statistics
were used to estimate the cumulative incidences ofoutcome events and their standard errors (SEs) at 1
and 5 years after the post-treatment MRI scan. Models
were adjusted for the clinical or demographic variable
that was most significantly associated with time until
occurrence of a clinical outcome event in univariate
testing, provided that the p value of the univariate
association was <0.1.
RESULTS
The present analysis of the ICSS-MRI substudy
included the same population as previously reported
(Figure 1) (3). A total of 231 patients were randomly
allocated to receive CAS (n ¼ 124) or CEA (n ¼ 107).
Sixty-six patients were studied in 3-T scanners (CAS,
n ¼ 37; CEA, n ¼ 29) and 165 patients in 1.5-T scan-
ners. In the CAS group, 51 patients were treated with
cerebral protection devices, whereas 73 patients un-
derwent unprotected stenting.
In the CAS group, 62 (50%) of 124 patients had new
ischemic DWI lesions on post-treatment MRI. Patients
with DWIþwere older by a median of 5 years, smoked
less often, had lower total cholesterol levels, and had
a higher median ARWMC score at randomization
(Table 1). During a median follow-up of 4.65 years
(interquartile range: 2.97 to 5.28 years), 10 patients
died in the DWIþ group (cumulative 5-year mortality
rate 16.5% [SE: 6.3%]), and 10 patients died in the
DWI– group (15.5% [SE: 4.8%]). Table 2 summarizes
medical treatment before the procedure and during
follow-up.
In the CAS group, recurrent stroke or TIA in any
territory occurred more often among DWIþ patients
(12 of 62) than among DWI– patients (6 of 62) in the
binary analysis (unadjusted HR: 2.85; 95% CI: 1.05 to
7.72; p ¼ 0.04) (Table 3, Central Illustration). Among
the tested baseline variables, systolic blood pressure
at randomization was associated with stroke or TIA in
any territory on the univariate level at a p value <0.1
(Online Table 1). The association between periproce-
dural DWI lesions and recurrent stroke or TIA remained
significant after adjustment for systolic blood pres-
sure (adjustedHR: 3.52; 95%CI: 1.21 to 10.22; p¼0.021).
The cumulative probability of having a stroke or
TIA in the CAS group was 15.1% (SE: 4.7%) in DWIþ
patients compared with 3.2% (SE: 2.2%) in DWI– pa-
tients at 1 year, and 22.8% (SE: 7.1%) compared with
8.8% (SE: 3.8%), respectively, at 5 years. The cumula-
tive incidence curves particularly diverged during the
first 6 months after the post-treatment scan, when 8 of
12 events occurred in DWIþ patients and 2 of 6 events
occurred in DWI– patients.
Between DWIþ and DWI– patients in the CAS
group, there was no significant difference in the risk
TABLE 1 Characteristics of Patients With and Without Periprocedural DWI Lesions in the Stenting and Endarterectomy Groups
Stenting Endarterectomy
DWIþ
(n ¼ 62 [50%])
DWI–
(n ¼ 62 [50%]) p Value
DWIþ
(n ¼ 18 [16.8%])
DWI–
(n ¼ 89 [83.2%]) p Value
Age, yrs 74 (68–80) 69 (60–75) 0.003 70 (64–74) 72 (63–76) 0.727
Male 42 (67.7) 45 (72.6) 0.566 13 (72.7) 63 (70.8) 0.903
Vascular risk factors
Smoking 42 (67.7) 52 (83.9) 0.036 13 (72.2) 67 (75.3) 0.785
Diabetes 14 (22.6) 10 (16.1) 0.367 3 (16.7) 21 (23.6) 0.520
Hypertension 47 (75.8) 38 (61.3) 0.083 12 (66.7) 62 (69.7) 0.802
Hyperlipidemia 42 (67.7) 36 (58.1) 0.268 12 (66.7) 60 (67.4) 0.951
CHD 18 (29.0) 12 (19.4) 0.212 4 (22.2) 17 (19.1) 0.761
PAD 8 (12.9) 14 (22.6) 0.161 2 (11.1) 13 (14.6) 0.697
Systolic blood pressure at
randomization, mm Hg
160 (135–175) 160 (133–180) 0.985 165 (150–180) 155 (140–170) 0.069
Total cholesterol at
randomization, mmol/l
4.3 (3.4–5.0) 5.0 (4.2–6.0) <0.001 5.1 (4.3–6.1) 4.8 (4.1–5.6) 0.515
Baseline mRS 0.301 0.229
0 26 (41.9) 28 (45.2) 10 (55.6) 28 (31.5)
1 17 (27.4) 12 (19.4) 5 (27.8) 24 (27.0)
2 16 (25.8) 15 (24.2) 3 (16.7) 25 (28.1)
3 1 (1.6) 6 (9.7) 0 (0.0) 9 (10.1)
4 2 (3.2) 1 (1.6) 0 (0.0) 3 (3.4)
Qualifying event 0.136 0.363
Retinal ischemia 11 (17.7) 16 (25.8) 4 (22.2) 18 (20.2)
TIA 18 (29.0) 24 (38.7) 10 (55.6) 36 (40.4)
Stroke 33 (53.2) 22 (35.5) 4 (22.2) 35 (39.3)
ARWMC score 5 (3–9) 4 (1–7) 0.011 4 (3–8) 4 (2–8) 0.763
Stenosis, ipsilateral 0.433 0.734
Moderate (50%–69%) 10 (16.1) 7 (11.8) 1 (5.6) 7 (7.9)
Severe (70%–99%) 52 (83.9) 55 (88.7) 17 (94.4) 82 (92.1)
Stenosis, contralateral 0.799 0.860
Mild (<50%) 42 (67.7) 37 (59.7) 13 (72.2) 61 (68.5)
Moderate (50%–69%) 5 (8.1) 7 (11.3) 2 (11.2) 14 (15.7)
Severe (70%–99%) 11 (17.7) 14 (22.6) 3 (16.7) 12 (13.5)
Occlusion 4 (6.5) 4 (6.5) 0 (0.0) 2 (2.2)
Values are median (interquartile range) or n (%). Values in bold are <0.05.
ARWMC ¼ age-related white matter changes; CHD ¼ coronary heart disease; DWIþ ¼ presence of periprocedural diffusion-weighted imaging lesions; DWI– ¼ absence
of periprocedural diffusion-weighted imaging lesions; mRS ¼ modified Rankin Scale; PAD ¼ peripheral artery disease; TIA ¼ transient ischemic attack.
TABLE 2 Medical Treatment Before Procedure and During Follow-Up
Before Procedure After 6 Months After 1 Year After 5 Years
CAS
(n ¼ 118)
CEA
(n ¼ 102)
CAS
(n ¼ 112)
CEA
(n ¼ 102)
CAS
(n ¼ 104)
CEA
(n ¼ 92)
CAS
(n ¼ 55)
CEA
(n ¼ 42)
Any antiplatelet therapy 118 (100) 95 (93) 109 (97) 93 (91) 99 (95) 85 (92) 51 (93) 38 (90)
Aspirin 111 (94) 87 (85) 102 (91) 86 (84) 87 (84) 70 (76) 48 (87) 33 (78.6)
Clopidogrel 114 (97) 13 (12) 5 (5) 11 (11) 7 (7) 9 (10) 1 (2) 4 (10)
Dipyridamole þ aspirin 15 (13) 27 (27) 20 (18) 15 (15) 23 (22) 16 (17) 13 (24) 10 (24)
Dual antiplatelet therapy 109 (92) 6 (6) 8 (7) 5 (5) 5 (5) 5 (5) 1 (2) 1 (2)
Anticoagulation (vitamin K antagonists) 4 (3) 6 (6) 3 (3) 6 (6) 2 (2) 7 (8) 1 (2) 4 (10)
Any anticoagulation or antiplatelet 118 (100) 100 (98) 110 (98) 99 (97) 101 (97) 90 (98) 51 (93) 41 (98)
Antihypertensive therapy – – 79 (71) 74 (73) 71 (68) 69 (75) 44 (80) 30 (71)
Lipid lowering therapy – – 94 (84) 83 (81) 85 (82) 76 (83) 41 (75) 32 (76)
Values are n with available data (%).
CAS ¼ carotid artery stenting; CEA ¼ carotid endarterectomy.
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TABLE 3 HRs of Outcome Events During Follow-Up Depending on Post-Treatment DWI Lesions
Stroke or TIA in Any Territory Ipsilateral Stroke or TIA Stroke in Any Territory
Stenting (n ¼ 124)
DWIþ (n ¼ 62) vs. DWI (n ¼ 62)*
Unadjusted 2.85 (1.05–7.72), p [ 0.040 1.41 (0.43–4.66), p ¼ 0.572 1.64 (0.36–7.43), p ¼ 0.522
Adjusted 3.52 (1.21–10.22), p [ 0.021 3.15 (0.90–11.10), p ¼ 0.073
DWI lesion count†
Unadjusted 1.03 (1.01–1.04), p [ 0.003 1.02 (1.00–1.05), p [ 0.020 1.03 (1.01–1.06), p [ 0.003
Adjusted 1.03 (1.01–1.05), p [ 0.001 1.03 (1.01–1.05), p [ 0.014
Bootstrap CI‡ 1.00–1.05 0.98–1.05 0.99–1.07
Endarterectomy (n ¼ 107)
DWIþ (n ¼ 18) vs. DWI (n ¼ 89)*
Unadjusted 0.52 (0.07–4.04), p ¼ 0.528 1.27 (0.14–11.38), p ¼ 0.830 —§
Adjusted 0.59 (0.74–4.67), p ¼ 0.616 1.55 (0.16–14.96), p ¼ 0.706
DWI lesion count†
Unadjusted 1.08 (0.89–1.32), p ¼ 0.433 1.18 (0.97–1.43), p ¼ 0.097 0.48 (0.03–8.83), p ¼ 0.619
Adjusted 1.08 (0.98–1.28), p ¼ 0.572 1.14 (0.92–1.41), p ¼ 0.228
Values are HR (95% CI). Values in bold are <0.05. *Cox hazard ratios (HRs), 95% confidence intervals (CIs), and p values for outcome events during follow-up in patients with
periprocedural DWI lesions versus those without. †Cox HRs, 95% CIs, and p values for outcome events during follow-up depending on the number of periprocedural DWI lesions
(DWI lesion count). ‡Bootstrap CIs were calculated with R statistical software by using a bias-corrected method. §HR not calculated as no strokes occurred in group with
periprocedural DWI lesions.
Abbreviations as in Table 1.
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526of ipsilateral stroke or TIA or in the risk of stroke
alone (Table 3, Figure 2). However, in the lesion count
analysis, a higher number of periprocedural DWI le-
sions were significantly associated with all 3 outcome
events in the CAS group, both before and after
adjustment for baseline variables (Table 3, Online
Table 1). To investigate whether the Cox regression
models were overly influenced by a small number of
patients with high DWI lesion counts, we performed
bootstrapping of HR CIs with 100,000 iterations by
using the bias-corrected method with R statistical
software (R Foundation for Statistical Computing,
Vienna, Austria). Although the results displayed some
evidence of overinfluencing, the model with the pri-
mary outcome measure (i.e., any stroke or TIA)
remained significant.
In the CEA group, 18 (16.8%) patients had new
ischemic DWI lesions on post-treatment MRI,
whereas 89 (83.2%) patients had no lesions. Baseline
characteristics did not differ significantly between
patients with and without lesions (Table 1). During a
median follow-up of 4.02 years (interquartile range:
2.93 to 5.11), 1 patient in the DWIþ group died (cu-
mulative 5-year mortality rate 5.9% [SE: 5.7%]) and 10
patients in the DWI– group died (19.0% [SE: 5.8%]).
There was no significant association between the
presence or number of periprocedural DWI lesions and
any outcome measures in the binary analysis or in the
count analysis (Table 3, Figure 2).
None of the recurrent events observed in the ICSS-
MRI substudy were associated with residual or
recurrent carotid stenosis after treatment, and noneof the patients with recurrent events underwent
repeat revascularization by CAS or CEA.
DISCUSSION
The present study revealed that in patients treated
with CAS: 1) the occurrence of periprocedural
ischemic brain lesions on DWI increased the risk of
recurrent stroke or TIA in any territory during follow-
up; 2) most of these events occurred within the first
6 months after treatment; 3) a higher count of peri-
procedural DWI lesions additionally increased the risk
of ipsilateral stroke or TIA and any stroke; and 4) in
patients undergoing CEA, neither the presence nor
the number of periprocedural DWI lesions was associ-
ated with the risk of future cerebrovascular events.
Previously, several studies found a higher fre-
quency of new ischemic brain lesions on DWI after
CAS than after CEA (1). In a meta-analysis of non-
randomized and randomized studies, the odds of
detecting new lesions after treatment were increased
after CAS compared with CEA by a ratio of 6.16 (95% CI:
4.45 to 8.54) (3). The proportion of patients with peri-
procedural DWI lesions after CAS was 50% in the ICSS-
MRI substudy but has been reported in the literature to
be as high as 87.1% (15). Despite the frequent occur-
rence of these lesions, their significance for individual
patients remains unclear. Previous analyses of the
ICSS-MRI substudy revealed that CAS patients had
more lesions persisting onFLAIR imaging 1month after
treatment than CEA patients but that the rate of con-
version from acute to persisting lesions was lower in
CENTRAL ILLUSTRATION Significance of Brain Lesions After
Carotid Artery Stenting: Kaplan-Meier Cumulative Incidence Curves of
Recurrent Stroke or TIA During Follow-Up
Unadjusted Cox regression hazard ratio (HR) for any stroke or TIA in patients with and
without new ischemic diffusion-weighted imaging (DWI) lesions on post-treatment
magnetic resonance imaging. Percentages are point estimates of cumulative incidences
after 1 and 5 years of follow-up. CI ¼ confidence interval.
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527the CAS group than in the CEA group; this finding was
attributed to the smaller size of the individual lesions
in the CAS group (7). A single-center substudy in ICSS
detected a small but statistically significant decrease in
global cognitive performance 6 months after CAS
compared with baseline values, which was not present
in the CEA group. However, cognitive decline was not
associated with the occurrence of periprocedural DWI
lesions, although the study was likely underpowered
to rule out such an association (8).
We are unaware of any previous studies investi-
gating the impact of periprocedural DWI lesions in
carotid revascularization on the risk of future cere-
brovascular events. Our findings lend support to the
hypothesis that periprocedural DWI lesions seen after
CAS may be a marker of unstable atherosclerotic
plaques, which increase the risk of cerebral embolism
not only during the procedure but also in the first few
months thereafter. DWI lesions and ischemic com-
plications during stent placement are more common
among patients with unstable plaques characterized
by echolucent appearance on ultrasound and lipid-
rich necrotic plaque and intraplaque hemorrhage on
MRI (16–18). Another study showed that once athe-
rothrombosis has occurred, the plaque may remain
chronically unstable unless trigger factors such as
inflammation or increased shear stress are removed
(19). Unstable plaques might not only be present in
the target artery but also in the access vasculature,
including the aortic arch. Aortic arch lesions have
been shown to increase the risk of cerebral embolism
during CAS (20,21). Unstable aortic atheroma causing
delayed embolism may explain why recurrent events
also occurred outside the territory supplied by the
treated carotid artery in the present study.
The curves of event rates seen in our study may
indicate that patients with periprocedural DWI
lesions after CAS remain at increased risk of cere-
brovascular events for the first 6 months after treat-
ment. This finding might support more aggressive
and prolonged antiplatelet treatment among such
patients. More aggressive antiplatelet regimens may
also prevent cerebral ischemia occurring as a result of
the procedure. In a recent randomized study (22), an
increase in the clopidogrel loading dose from 300 to
600 mg administered before the intervention signifi-
cantly reduced the incidence of the combined
outcome event of new DWI lesions on post-treatment
MRI or any stroke or TIA occurring within 30 days of
treatment. In the ICSS-MRI substudy, 92% of patients
in the CAS group received dual antiplatelet therapy
before the procedure, but loading doses were not
recorded. In a post-hoc analysis, we found no signif-
icant difference in the risk of periprocedural DWIlesions between patients undergoing CAS under
monotherapy versus dual antiplatelet therapy, but
our study was not powered to demonstrate such a
difference. As shown by our follow-up data regarding
medication, dual antiplatelet therapy was not usually
given for a prolonged period of time beyond the rec-
ommended 4 weeks after the procedure.
Because routine DWI scanning after CAS increases
costs, and given the high incidence of new peripro-
cedural brain lesions, there may be justification for
administering more aggressive and prolonged anti-
platelet therapy to all patients undergoing CAS. How-
ever, our results need to be confirmed in larger studies
before such recommendations can be made.
STUDY LIMITATIONS. First, both 1.5- and 3-T scan-
ners were used in the study. Differences in magnetic
field strengths may have led to differences in the
sensitivity of detecting small ischemic brain lesions
FIGURE 2 Cumulative Incidence Rates of Outcome Events During Follow-Up
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528on DWI. Second, the absolute number of strokes
occurring in our study was small, which is why we
chose stroke or TIA as the combined primary outcome
event. For the patient, TIA is less relevant an outcome
than stroke. However, our analysis of DWI lesion countindicated that the presence of a large number of these
lesions, which as previously reported were often small
and clinically silent in the majority of patients (3,23),
seems to be associated with a higher risk for recurrent
stroke as well. Third, the small number of outcome
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Ischemic brain
lesions are often found on MRI after stenting of atherosclerotic
carotid stenosis; most are clinically asymptomatic, but they
identify patients at increased risk of future stroke or TIA.
TRANSLATIONAL OUTLOOK: Because most cerebral
ischemic events present clinically within the first 6 months after
carotid stenting, future trials should address whether patients
with asymptomatic post-procedural ischemia benefit from more
prolonged dual antiplatelet therapy.
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529events did not allow differentiation between the
effects of periprocedural DWI lesions on recurrent
events occurring inside versus outside the vascular
territory supplied by the treated carotid artery. Finally,
the small number of patients with new periproce-
dural DWI lesions after CEA precluded a meaningful
analysis of the impact of these lesions on future risk
of cerebrovascular events in the surgical arm.
CONCLUSIONS
Ischemic brain lesions discovered on DWI after CAS
seem to be a marker of increased risk for recurrent
cerebrovascular events. Patients with periprocedural
DWI lesions might benefit from more aggressive and
prolonged antiplatelet therapy after CAS.
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